Skip to Main Content
CWRU Links
cccnewsletterbanners03

December 15, 2014

CASE CCC IN THE NEWS

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer
ASCO Post - Dec 12, 2014
Jame Abraham, MD, FACP, Director of the Cleveland Clinic Breast Oncology Program and member of the Case Comprehensive Cancer Center, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Post-Transplant Adcetris Boosts PFS in Aggressive Lymphoma
MedPage Today- Dec 8, 2014
Brentuximab vedotin (Adcetris) significantly improved progression-free survival (PFS) in Hodgkin lymphoma patients who had undergone autologous stem-cell transplant, researchers said here...Hillard Lazarus, MD, Professor of Medicine at Case Western Reserve University (CWRU) and member of the Case Comprehensive Cancer Center in Cleveland, called the results "practice changing." "For patients with Hodgkin lymphoma, we use this agent a lot to get them to transplant," he told MedPage Today. "Adding this antibody to the practice of medicine is going to result in more cures, I believe, and certainly in more disease survivors in patients with Hodgkin lymphoma."

Gerson: Novel Gene Therapy for Glioma
Cancer Therapy Advisor- Dec 7, 2014
Stanton Gerson, MD, Director of the Case Comprehensive Cancer Center and Seidman Cancer Center, discusses study findings that looked into a novel genetic therapy for patients with glioma. He presented his study at the American Society of Hematology 2014 meeting.

Caimi: Methoxyamine for Chronic Leukemia
Cancer Therapy Advisor- Dec 7, 2014
Dr. Paolo Caimi, University Hospitals Seidman Cancer Center and member of the Case Comprehensive Cancer Center in Cleveland, discusses phase I trial results for methoxyamine at the American Society of Hematology 2014 meeting in San Francisco.

Research Sheds Light on Ethnic Discrepancies in CLL
Cleveland Clinic Consult QD- Dec 5, 2014
A recent study published in the journal Blood, headed by investigators at Cleveland Clinic and performed in collaboration with the National Marrow Donor Program, suggests a novel and important linkage between CLL, ethnic background and certain immune system proteins called human leukocyte antigen (HLA) alleles. HLA is essentially the defining antigens on our immune cells that do many things, including regulating our immune system and protecting us from infection, explains Brian T. Hill, MD, PhD the study's lead author, oncologist at the Taussig Cancer Institute, and member of the Case Comprehensive Cancer Center.. "The thing that's unique about HLA molecules is that there are many different varieties, and those varieties are specific to ethnic populations. So the HLA of someone from Northern European ancestry is specific and different from those of, say, African or Asian ancestry."

Nilotinib (Tasigna) and Chemotherapy for First-Line Treatment in Elderly patients with de novo Philadelphia Chromosome/BCR-ABL1 Positive ALL
MedPage Today - Dec 2014
Commentary by Stanton Gerson, MD, Director of the Case Comprehensive Cancer Center and Seidman Cancer Center.


MEMBER/RESEARCH HIGHLIGHTS

Distelhorst Named 2015 Harrington Scholar-Innovator

Dr. Clark DistelhorstClark Distelhorst, MD, PhD, Professor in the Division of Hematology/Oncology at CWRU and University Hospitals Case Medical Center (UHCMC), was recently named a 2015 Harrington Scholar-Innovator by the Harrington Discovery Institute (HDI) at UHCMC. Dr. Distelhorst is one of 11 outstanding physician-scientists in the nation to receive the award, which provides funding and drug development to help bring their research from basic discovery to clinical introduction.

As a recipient of this award, Dr. Distelhorst will receive up to $700,000 over two years to support his research on blood cancer. In addition, he along with his fellow Scholar-Innovators will be given access to HDI's Innovation Support Center, which includes a renowned group of industry experts charged with helping guide drug development.

Vinayak Honored as Master Clinician

Dr. Shaveta VinayakShaveta Vinayak, MD, Assistant Professor in the Division of Hematology/Oncology at CWRU and UHCMC, was honored as the inaugural Becky Hennessy Endowed Master Clinician in Breast Cancer Genomics. This endowment recognizes Dr. Vinayak's excellence in patient care and accomplishments, dedication, and clinical research focus on genomic approaches to breast cancer treatment.

First Gene Associated with Familial Glioma Identified

Dr. Jill Barnholtz-SloanA study conducted by the Gliogene Consortium, an international consortium of researchers, has identified for the first time a gene associated with familial glioma,providing new support that certain people may be genetically predisposed to the disease. Study authors found an increased risk of cancer associated with mutations in the POT1 gene. The findings were published last week in the Journal of the National Cancer Institute.

"This discovery is tremendously exciting, as we have known for years that a small subset of families have multiple people with gliomas, yet we have not understood the potential causes," commented study collaborator, Dr. Jill Barnholtz-Sloan. "This new paper sheds light on a potential cause for some of these families." Dr. Barnholtz-Sloan, Associate Director for Bioinformatics at the Case Comprehensive Cancer Center and Associate Professor in the Division of General Medical Sciences (Oncology) at CWRU, recruited families to the study and is the Ohio Principal Investigator for the Gliogene Consortium.


NEWS FROM THE NIH

New Biographical Sketch Format Required for NIH and AHRQ Grant Applications Submitted for Due Dates on or After May 25, 2015

The National Institutes of Health (NIH) Agency for Healthcare Research and Quality's (AHRQ) will require use of a new biosketch format in applications for research grantssubmitted for due dates on or after May 25, 2015. Between now and that time, applicants will have the choice of using the old or new biosketch format. This Notice supersedes NOT-OD-15-024 about the NIH and AHRQ requirement for use of a new biosketch format and provides some latitude in the transition for those who have already been compiling biosketches for their large grant applications with deadlines in early in 2015.

NIH and AHRQ encourages applicants to use the newly published biosketch format for all grant and cooperative agreement applications submitted for due dates on or after January 25, 2015, and will require use of the new format for applications submitted for due dates on or after May 25, 2015. Applicants may submit using the new biosketch format for due dates before January 25, 2015, if they wish.


CORE FACILITY NEWS

Radiation Resources Core Facility Adds Small Animal Irradiation Capabilities

The Radiation Resources Core Facility is now capable of irradiating small animals (rodents) on clinical radiation devices, including Cyberknife and Gammaknife. The added benefit is the capacity to deliver focal radiation while sparing normal tissues, more closely mimicking patient treatments and expanding the translational impact of animal experimentation. Please inquire as to how we can improve your experimental designs. Visit the Radiation Resources Core Facility for contact information.


FUNDING OPPORTUNITIES

American Association for Cancer Research

The Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to study immunological aspects of, or treatments for, kidney cancer. Research projects should advance the basic knowledge of tumor immunology mechanisms, or develop new concepts in the treatment, control, or prevention of kidney cancer by immunology-based therapeutic approaches. Proposed projects may be basic, translational, clinical or epidemiological in nature and must focus on cancer immunology including, but not limited to: immune recognition, regulation, tumor escape, and therapeutic manipulation for kidney cancer.
Deadline: January 5, 2015

The AACR-Ocular Melanoma Foundation Fellowship, in honor of Robert C. Allen, MD represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct ocular/uveal melanoma research and to establish a successful career path in ophthalmology, ocular oncology, uveal melanoma cancer biology or similar field. The research proposed for funding may be basic, translational or clinical in nature and must have direct, primary applicability and relevance to ocular/uveal melanoma.
Deadline: January 12, 2015

The Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research represent a joint effort to promote and support innovative research designed to accelerate the discovery, development, and application of new agents to treat breast cancer and/or for pre-clinical research with direct therapeutic intent. Eligibility is limited to junior faculty who, at the start of the grant term, will have completed their most recent doctoral degree or medical residency within the past 11 years. The research proposed for funding must be translational in nature and must have direct applicability and relevance to breast cancer.
Deadline: January 20, 2015

The AACR-Triple Negative Breast Cancer Foundation Career Development Award for Clinical/Translational Researchrepresents a joint effort to encourage and support junior faculty to conduct triple negative breast cancer research and establish a successful career path in this field. Eligibility is limited to junior faculty who, at the start of the grant term, will have completed their most recent doctoral degree or medical residency within the past 11 years. The research proposed for funding must be clinical or translational in nature and must have direct applicability and relevance to triple negative breast cancer.
Deadline: January 27, 2015

The Debbie's Dream Foundation-AACR Gastric Cancer Research Fellowships represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct gastric cancer research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to gastric cancer.
Deadline: January 27, 2015

Bladder Cancer Advocacy Network

The Bladder Cancer Advocacy Network is accepting applications for the Bladder Cancer Research Innovation Award. This new award, supported by the James Family Foundation, in conjunction with Partner Fund Management, which will support the work of one investigator with an exceptionally novel and creative project with great potential to produce a breakthrough in the management of bladder cancer. The aim of the Bladder Cancer Research Innovation Award is to support exceptionally novel and creative projects with great potential to produce breakthroughs in the management of bladder cancer. Proposals will be accepted for creative ideas and innovative approaches that have direct application and relevance to bladder cancer.
LOI Deadline: January 14, 2015

Avon Foundation for Women Breast Cancer Research 2015 Program

The Avon Foundation for Women continues its search for new preventive strategies to address the growing number of breast cancer cases around the globe and increase our understanding of not only the causes of breast cancer, but also the development and treatment of metastatic disease. The 2015 Avon Foundation Research Program seeks proposals in these areas.
Deadline: January 15, 2015


PREVIOUSLY ANNOUNCED OPPORTUNITIES

Alex's Lemonade Stand Foundation Epidemiology Grants Epidemiology Grants
Deadline: December 15

Limited Submission: The Josiah Macy Jr. Foundation: Macy Faculty Scholars Program
CWRU LOI Deadline: December 29
External Application Deadline: February 11, 2015

American Brain Tumor Association Basic Research Fellowships
Deadline: January 7, 2015

Doris Duke Clinical Research Mentorship Program
Deadline: January 13, 2015

International Association of the Study of Lung Cancer (IASLC)
Deadline: January 15, 2015

Radiological Society of North America
Deadline: January 15, 2015

CTSC Annual Pilot Program
LOI Deadline: January 15, 2015

GI SPORE: Request for Project Proposals
Deadline: January 16, 2015

American Brain Tumor Association Medical Student Summer Fellowships
Deadline: January 28, 2015

Leukemia & Lymphoma Society Translational Research Program (TRP)
LOI Deadline: February 15, 2015
Application Deadline: March 1, 2015

Lila and Murray Gruber Memorial Cancer Research Award
Deadline: February 28, 2015

Ohio Cancer Research Associates
Deadline: February 28, 2015

Worldwide Cancer Research
Deadline: April 24, 2015

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program
Application Deadline: Open

Solving Kids' Cancer Therapeutic Development Initiative
Application Deadline: Open

Support of Multi-investigator Initiatives in the Case CCC
Deadline: Open

Collaborative Activity Awards
Deadline: Open


NIH BULLETIN – Notices and Funding Opportunities


HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at gillian.irwin@case.edu.

EVENTS

Tues, Dec 16

Molecular Genetics Departmental Research Seminar Series
HyeonJoo Cheon, PhD
Project Staff, Stark Lab, Molecular Genetics
Cleveland Clinic
Topic: Paradoxical Roles of the Interferon Signaling in Cancer Therapy
9:30 am NE1-205 Cleveland Clinic

Epidemiology & Biostatistics Seminar
Fred Schumacher, PhD, MPH
Keck School of Medicine
University of Southern California
Topic: Molecular Epidemiology: An Application to Colorectal Cancer
12 pm Robbins E-401

Immunology Research Seminar Series
Wayne M. Yokoyama, MD
Department of Pathology and Immunology
Howard Hughes Medical Institute
Topic: Tissue-Resident Natural Killer Cells
12 pm WRB 1-413

Pharmacology Seminar Series
Gregory Tochtrop, PhD
Associate Professor, Chemistry
CWRU
Topic: TBD
12 pm Wood W331/Webster Conference room

THOR Seminar
Ken Doyle
Topic: Chemical Hygiene Annual Review
Gabriele Olinchic
Topic: Clinical Plastic Recycling
Department of Translational Hematology & Oncology Research (THOR)
Cleveland Clinic
1 pm R3-027 Cleveland Clinic

Cancer Biology Seminar Series
Mingjun Zhang, PhD
Research Fellow, Yi Lab, Cancer Biology
Cleveland Clinic
Topic: Enhance the Efficacy of the anti-β2-Microglobulin Monoclonal Antibodies by Combining with Anti-myeloma Chemotherapy Drugs
2 pm NC1-202 Cleveland Clinic


Wed, Dec 17


Thurs, Dec 18

Cancer Trainee Seminar
Edward Greenberg
Research Topic: Synergistic Killing of Small Cell Lung Cancer Cells by BH3-mimetic ABT-263 and the Bcl-2-IP3 Receptor Disruptor BIRD-2
Masumi Ueda
Clinical Topic: Overview of Phase I Clinical Trials in Oncology 
12 pm WRB 3-136

Molecular Biology & Microbiology Seminar
Kien Ngyuen
Topic: Hunting for the Cis-element Required for Silencing of HIV-1 in T Cells
Benjamin Luttge
Topic: Quantitation of HIV-1 Proviral Reservoirs by qPCR and Next Generation Sequencing
Karn Lab, Molecular Biology & Microbiology
CWRU
1 pm Rottman Seminar Room W203

Cancer Center Faculty Candidate
Hans-Martin Herz, PhD
Postdoctoral Fellow
Stowers Institute for Medical Research
Topic: Enhancer-associated Functions of Metazoan Trr/MLL3/MLL4 COMPASS-like Complexes
3 pm WRB 3-136


Fri, Dec 19

Taussig Cancer Institute Grand Rounds
Danyu Sun, MD
Taussig Cancer Institute
Cleveland Clinic
Topic: Mantle Cell Lymphoma Treatment: How can we do better?
8 am R3/002-003 Cleveland Clinic

Cellular and Molecular Medicine Seminar Series
Paul L. Fox, PhD
Professor, Cellular & Molecular Medicine
CWRU/Cleveland Clinic
Topic: Glutamyl-prolyl tRNA Synthetase and Metabolism: New functions for an ancient enzyme
10 am NC1-202 Cleveland Clinic

Cancer Center Seminar Series
Jann N. Sarkaria, MD
Professor, Radiation Oncology
Mayo Clinic Rochester
Topic: Impact of the Blood Brain Barrier on Efficacy of Individualized Medicine Strategies in GBM
12 pm BRB 105

Cancer Center Chalk Talk
Hans-Martin Herz, PhD
Postdoctoral Fellow
Stowers Institute for Medical Research
2 pm Wolstein Research Building 3-136

 

Case CCC Calendar

LRI Calendar


UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS

ASH Review
January 21, 2015

Best of San Antonio Breast Cancer Symposium
February 4, 2015

Multidisciplinary Head and Neck Cancer Update
Weston, FL
March 6-7, 2015

Lung Cancer Course
April 25, 2015

ADDITIONAL UPCOMING SEMINARS & EVENTS

Symposium on Global Cancer Research
March 25, 2015
Boston Sheraton Hotel
Details